Novo Nordisk today presented data at the 76th annual American Association for the Study of Liver Diseases (AASLD) meeting, ...
Novo Nordisk India partners with Emcure Pharma to distribute and market Poviztra (semaglutide) nationwide, expanding access ...
Medpage Today on MSN
Semaglutide's MASH Benefits Extend Beyond Weight Loss
WASHINGTON -- Semaglutide (Wegovy) improved liver inflammation and fibrosis in patients with metabolic dysfunction-associated ...
Emcure Pharma becomes the first Indian company to hold exclusive rights to distribute and commercialise Poviztra, a ...
Novo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide ...
Camurus (NASDAQ STO: CAMX) today announced positive topline results from a randomized, active-controlled Phase 1b study evaluating CAM2056, the company's monthly FluidCrystal® semaglutide formulation, ...
How effective is Wegovy at treating MASH? Novo Nordisk announced the results of the ESSENCE phase 3 trial at the American ...
Novo Nordisk India and Emcure Pharma announced a strategic partnership on Monday to launch Poviztra (semaglutide injection 2.4 mg) in India. The collaboration aims to enhance the distribution and ...
Danish drugmaker Novo Nordisk has partnered Emcure Pharmaceuticals to commercialise Poviztra, a 2.4 milligram (mg) ...
The Indian subsidiary of Danish pharma major Novo Nordisk has partnered with Pune-based Emcure Pharma to expand the reach of ...
21h
The next-generation weight loss drug that’s ‘as effective as Mounjaro – WITHOUT Ozempic side effect’
A NEW weight loss drug may offer a tempting alternative to popular GLP-1 drugs like Ozempic and Wegovy. The once-weekly ...
Danish drugmaker Novo Nordisk has teamed up with Emcure Pharmaceuticals to increase access to its weight-loss drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback